143 related articles for article (PubMed ID: 11599019)
1. QSAR: hydropathic analysis of inhibitors of the p53-mdm2 interaction.
Galatin PS; Abraham DJ
Proteins; 2001 Nov; 45(3):169-75. PubMed ID: 11599019
[TBL] [Abstract][Full Text] [Related]
2. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53.
García-Echeverría C; Chène P; Blommers MJ; Furet P
J Med Chem; 2000 Aug; 43(17):3205-8. PubMed ID: 10966738
[No Abstract] [Full Text] [Related]
3. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
[TBL] [Abstract][Full Text] [Related]
4. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
5. p53 alpha-Helix mimetics antagonize p53/MDM2 interaction and activate p53.
Chen L; Yin H; Farooqi B; Sebti S; Hamilton AD; Chen J
Mol Cancer Ther; 2005 Jun; 4(6):1019-25. PubMed ID: 15956260
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of the interaction between MDM2 and p53.
Schon O; Friedler A; Bycroft M; Freund SM; Fersht AR
J Mol Biol; 2002 Oct; 323(3):491-501. PubMed ID: 12381304
[TBL] [Abstract][Full Text] [Related]
7. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
8. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
9. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
10. A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells.
Galatin PS; Abraham DJ
J Med Chem; 2004 Aug; 47(17):4163-5. PubMed ID: 15293988
[TBL] [Abstract][Full Text] [Related]
11. Group-based QSAR and molecular dynamics mechanistic analysis revealing the mode of action of novel piperidinone derived protein-protein inhibitors of p53-MDM2.
Goyal S; Grover S; Dhanjal JK; Tyagi C; Goyal M; Grover A
J Mol Graph Model; 2014 Jun; 51():64-72. PubMed ID: 24858256
[TBL] [Abstract][Full Text] [Related]
12. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach.
Zaytsev A; Dodd B; Magnani M; Ghiron C; Golding BT; Griffin RJ; Liu J; Lu X; Micco I; Newell DR; Padova A; Robertson G; Lunec J; Hardcastle IR
Chem Biol Drug Des; 2015 Aug; 86(2):180-9. PubMed ID: 25388787
[TBL] [Abstract][Full Text] [Related]
13. Structure of the stapled p53 peptide bound to Mdm2.
Baek S; Kutchukian PS; Verdine GL; Huber R; Holak TA; Lee KW; Popowicz GM
J Am Chem Soc; 2012 Jan; 134(1):103-6. PubMed ID: 22148351
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of the hdm2-p53 interaction.
Böttger A; Böttger V; Garcia-Echeverria C; Chène P; Hochkeppel HK; Sampson W; Ang K; Howard SF; Picksley SM; Lane DP
J Mol Biol; 1997 Jun; 269(5):744-56. PubMed ID: 9223638
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
Chène P
Mol Cancer Res; 2004 Jan; 2(1):20-8. PubMed ID: 14757842
[TBL] [Abstract][Full Text] [Related]
16. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
[TBL] [Abstract][Full Text] [Related]
17. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
Dezi C; Carotti A; Magnani M; Baroni M; Padova A; Cruciani G; Macchiarulo A; Pellicciari R
J Chem Inf Model; 2010 Aug; 50(8):1451-65. PubMed ID: 20726601
[TBL] [Abstract][Full Text] [Related]
18. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2.
Unger T; Juven-Gershon T; Moallem E; Berger M; Vogt Sionov R; Lozano G; Oren M; Haupt Y
EMBO J; 1999 Apr; 18(7):1805-14. PubMed ID: 10202144
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of potent non-peptide MDM2 inhibitors.
Ding K; Lu Y; Nikolovska-Coleska Z; Qiu S; Ding Y; Gao W; Stuckey J; Krajewski K; Roller PP; Tomita Y; Parrish DA; Deschamps JR; Wang S
J Am Chem Soc; 2005 Jul; 127(29):10130-1. PubMed ID: 16028899
[TBL] [Abstract][Full Text] [Related]
20. Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides.
Picksley SM; Vojtesek B; Sparks A; Lane DP
Oncogene; 1994 Sep; 9(9):2523-9. PubMed ID: 8058315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]